Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
PT-141 can also affect blood pressure, so your cardiovascular history matters
Developed By
The 2017 foundational studies confirmed that 5amino1mq reduces NAD consumption via NNMT inhibition, improves glucose clearance, and decreases fat accumulation.In subsequent years, the scope expanded: a 2021 study in obese mice validated its antiobesity effects, and 2024 research revealed improvements in muscle function in aged mice.To date, the compound remains in the preclinical research stage, with no largescale human clinical trials or FDA approval for human use
For instance, in NSCLC, treatment with first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) often leads to the development of the EGFR T790M mutation, while third-generation inhibitors subsequently select for the C797S mutation, both of which confer resistance
